

RECEIVED
CENTRAL FAX CENTER LA0100 (NP)

AUG 31 2006

REMARKS

Claims 1 to 6, 10 to 18, and 22 to 27 as amended in the Amendment mailed June 12, 2006 and new Claims 28 to 31 (added in the Amendment mailed June 12, 2006) are present.

Reconsideration of the rejection of this application is respectfully requested in view of the above amendments and the following remarks.

As requested by the Examiner, submitted herewith is a Declaration of the inventor Lifen Shen, which supplements the Amendment filed June 12, 2006.

The Declaration of Dr. Shen shows that in the continuous process of the invention, wherein the first step of forming the lithiated anion is carried out in a microreactor under non-cryogenic temperature, and the second step coupling is also carried out under non-cryogenic temperature produces significantly higher yields than the cited Czernecki et al. batch process (discussed in detail in the Amendment filed June 12, 2006). As seen in Dr. Shen's Declaration and in Table A reproduced below, comparative evaluation of the batch process described in Czernecki et al. produced yields of 32% and 40% at non-cryogenic temperatures, and only showed elevated yield (83.6%) when both lithiation and coupling are performed at cryogenic temperatures (-78°C), whereas the continuous process of the invention produced yields of 76.3%, 72.1% and 70.4% at non-cryogenic temperatures.

Table A: Preparation of Glycoside

Process	Ex.	Scale (g)	Conditions		Isolated Yield
			Lithiation (solvent, temperature)	Coupling (solvent, temperature)	
Batch processes as run in the standard lab glassware	Control 1	3.0	THF/heptane, -10°C	THF/heptane, -10°C	40.3%
	Control 2	3.0	THF/heptane, 20°C	THF/heptane, 20°C	32.2%
	Control 3	3.0	THF/heptane, -78°C	THF/heptane, -78°C	83.6%
Continuous processes run using a microreactor system (two non-cryogenic steps)	Ex. 4	4.0	THF/heptane, 20°C	THF/heptane, -10°C	76.3%
	Ex. 5	4.0	THF/heptane, 20°C	THF/heptane, 5°C	72.1%
	Ex. 6	4.0	THF/heptane, 20°C	THF/heptane, 20°C	70.4%

LA0100 (NP)

Based on the foregoing discussion, and the Shen Declaration, Applicants submit that the invention as claimed herein is not taught, disclosed, suggested or made obvious by Czernecki et al.

Applicants respectfully request that this rejection for obviousness be withdrawn, it having been properly traversed.

Conclusion

In light of the Amendment submitted June 12, 2006, and the accompanying Declaration, Applicants submit that all outstanding rejections and observations have been met and overcome, and therefore withdrawal and allowance of the pending claims is requested.

If a direct personal communication might advance the prosecution of this application, the Examiner is invited to contact Applicants' undersigned representative at the telephone number below.

AUG. 31. 2006 4:17PM

BMS PATENT DEPT

RECEIVED
CENTRAL FAX CENTER

NO. 8846 P. 10


AUG 31 2006

LA0100 (NP)

FEE AUTHORIZATION

The Commissioner is authorized to charge any fee required for entry of this amendment, or credit any overpayment thereof to the assignee's Deposit Account No. 19-3880.

Respectfully submitted,



Burton Rodney
Attorney for Applicants
Reg. No. 22,076
Phone: 609-252-4336

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: August 31, 2006